Causalus is the first and only company in the world developing a dedicated process and software for medication reviews (=MR, evaluating and optimising the patients' medicines use). There are 90M+ people in EU & US who use over 5 prescription medicines, and MRs are considered as the gold standard in minimising adverse drug reactions, which cost $100B's annually in health expenditures. Causalus' improved MR process takes 10x less time, enables continuous medication change impact tracking and digitally documents every action for complete transparency. Causalus is currently a MDD1 CE-marked medical device. Our aim is to eradicate harmful polypharmacy, so that people wouldn't have to suffer from adverse effects needlessly. Feel free to read more about us from the Medium post by our pre-seed investor Icebreaker VC: https://medium.com/icebreakervc/causalus-developing-a-solution-to-polypharmacy-954f884b70a8